SBRT2015

Metastatic melanoma – phase III trial

Median PFS 11.5 months with nivolumab plus ipilimumab, as compared with 2.9 months with ipilimumab and 6.9 months with nivolumab (HR for comparison with ipilimumab, 0.57; 99.5% CI, 0.43 to 0.76; P<0.001)

Progression-free survival

Larkin J, NEJM 2015